Medication info
Actozone 15 mg (Pioglitazone Hydrochloride)

Actozone 15 mg (Pioglitazone Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Pioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Jeil Pharmaceutical Co., Ltd.
Appearance
This medicine is a white, round tablet.
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 200706892 · Notified 2007.06.15 · Insurance code 645401330

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults · Children
Adult dose
This medicine is administered orally once daily, regardless of meals. Diabetes management should be individualized for each patient. Ideally, response to treatment should be assessed by monitoring glycated hemoglobin (HbA1c), a more accurate diagnostic measure than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the previous 2–3 months. In clinical practice, this medicine should be administered for an appropriate period to assess changes in glycated hemoglobin (at least 3 months), provided that glycemic control in the patient with diabetes does not worsen. 1. Monotherapy This medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled with diet and exercise. If an adequate effect is not achieved with the initial dose, the dose may be increased to up to 30 mg once daily. Combination therapy should be considered in patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medicine may be administered in combination with a sulfonylurea, starting at 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dose and schedule. However, if the patient develops symptoms of hypoglycemia, the dose of the sulfonylurea should be reduced. 2) Metformin: This medicine may be administered in combination with metformin, starting at 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dose and schedule. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be maintained when combination therapy with this medicine is initiated. However, in patients receiving this medicine in combination with insulin, the insulin dose may be reduced by 10–25% if symptoms of hypoglycemia occur or plasma glucose falls to 100 mg/dL or below. Subsequent dose adjustments should be individualized according to the degree of glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see Renal Impairment under General Precautions). Treatment with this medicine should not be initiated in patients with clinical evidence of active liver disease or elevated serum aminotransferase levels (at least 2.5 times the upper limit of normal for ALT) at the time treatment is started (see Effects on the Liver under Adverse Reactions and General Precautions). Monitoring of liver enzymes is recommended in all patients before starting treatment with this medicine and periodically thereafter. There are no data on the use of this medicine in combination with other thiazolidinediones.
Child dose
Use is not recommended in children under 18 years of age because there is no experience with its use in this population.

Ingredients

Manufacturer
Jeil Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Abnormal blood sugar control in patients with type 2 diabetes
View approved original text

This medicine is used as an adjunct to diet and exercise to improve blood sugar control in patients with type 2 diabetes. It can be administered as monotherapy, and if there is no effect on blood sugar improvement with other oral hypoglycemic agents, it can be used in combination with sulfonylureas, metformin, or insulin. Additionally, nutritional counseling, weight loss, and exercise therapy are also important for patients with type 2 diabetes. These efforts are beneficial not only for initial treatment but also for maintaining the effectiveness of drug therapy. This medicine is effectively used to improve blood sugar control.

How to take

Adult dose

This medicine is administered orally once daily, regardless of meals. Diabetes management should be individualized for each patient. Ideally, response to treatment should be assessed by monitoring glycated hemoglobin (HbA1c), a more accurate diagnostic measure than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the previous 2–3 months. In clinical practice, this medicine should be administered for an appropriate period to assess changes in glycated hemoglobin (at least 3 months), provided that glycemic control in the patient with diabetes does not worsen. 1. Monotherapy This medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled with diet and exercise. If an adequate effect is not achieved with the initial dose, the dose may be increased to up to 30 mg once daily. Combination therapy should be considered in patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medicine may be administered in combination with a sulfonylurea, starting at 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dose and schedule. However, if the patient develops symptoms of hypoglycemia, the dose of the sulfonylurea should be reduced. 2) Metformin: This medicine may be administered in combination with metformin, starting at 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dose and schedule. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be maintained when combination therapy with this medicine is initiated. However, in patients receiving this medicine in combination with insulin, the insulin dose may be reduced by 10–25% if symptoms of hypoglycemia occur or plasma glucose falls to 100 mg/dL or below. Subsequent dose adjustments should be individualized according to the degree of glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see Renal Impairment under General Precautions). Treatment with this medicine should not be initiated in patients with clinical evidence of active liver disease or elevated serum aminotransferase levels (at least 2.5 times the upper limit of normal for ALT) at the time treatment is started (see Effects on the Liver under Adverse Reactions and General Precautions). Monitoring of liver enzymes is recommended in all patients before starting treatment with this medicine and periodically thereafter. There are no data on the use of this medicine in combination with other thiazolidinediones.

Child dose

Use is not recommended in children under 18 years of age because there is no experience with its use in this population.

Precautions

This medicine is used for the treatment of type 2 diabetes and is effective in patients whose insulin is normally secreted. During the use of this medicine, heart failure may occur or worsen; therefore, patients with heart disease should consult with their doctor before administration. In particular, patients with existing symptoms of heart failure or a history of heart failure should not use this medicine. This medicine can cause fluid retention, leading to edema; thus, if symptoms of edema occur, medical personnel should be informed immediately. Furthermore, patients with a history of bladder cancer or currently having bladder cancer should not take this medicine. Patients with poor liver function or severely impaired kidney function should also avoid this medicine. Women who are pregnant or of childbearing potential should not take this medicine, and premenopausal women should use appropriate contraceptive methods as the risk of pregnancy may increase during use. This medicine may increase the risk of hypoglycemia when combined with other diabetes medications, so caution is needed when used together. Regular monitoring of blood sugar and liver function tests is required during treatment, and any symptoms such as weight gain, sudden edema, or shortness of breath should be reported to a doctor immediately. It is not recommended for use in children or adolescents under 18 years of age as safety and efficacy have not been established. Elderly patients, especially those over 75 years old, should use this medicine cautiously, and dosage adjustments may be necessary. In the case of overdose, immediate hospital visit for appropriate treatment is required. Finally, this medicine should be kept out of the reach of children and stored in its original container.

Side effects

Congestive heart failure, excessive and rapid weight changes, dyspnea, edema, fluid retention, edema, headache, sinusitis, myalgia, pharyngitis, abdominal distension, weight gain, hypoglycemia, upper respiratory infection, urinary tract infection, low back pain, dizziness, diarrhea, elevated serum creatine kinase, hypertension, heart failure, limb pain, chest pain, death due to cardiovascular vulnerability, worsening of congestive heart failure, emergency room visits due to congestive heart failure, progression of congestive heart failure, gross hematuria, urination disorders, urgency, diabetic macular edema associated with vision reduction, fatal and non-fatal liver failure, hemoglobin reduction, hematocrit reduction, elevated serum ALT levels, elevated serum bilirubin levels, bladder cancer, fatigue, loss of appetite, nausea, vomiting, abdominal pain, itching, chest pain, tremors, chills, gastrointestinal disorders, epigastric discomfort, numbness, muscle rigidity, head discomfort, worsening of liver disease, urticaria, eczema, arthralgia, knee abnormalities, arm weakness, proteinuria, increased serum creatinine, anxiety, insomnia, drowsiness, simple herpes, visual blurriness, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, heart failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a container that protects it from light and air and should avoid humid areas. The storage temperature is generally between 15 to 30 degrees Celsius, with a recommended temperature of 25 degrees. Proper storage maintains the medicine's efficacy and safety.

Appearance and packaging

Appearance

This medicine is a white, round tablet.

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.